HL MEDICAL SYSTEMS
The Problem
"Clinicians shouldn’t have to rely on uncertainty, they deserve tools that make breast exams more consistent, objective, and defensible."
Variability
Clinical breast exams remain a foundational part of breast health evaluation, yet their effectiveness varies widely. Differences in technique, pressure, coverage patterns, and experience can lead to inconsistent sensitivity across clinicians and across visits. Even well-performed exams are inherently subjective, making it difficult to compare findings over time or between providers.
Subjectivity
Today’s clinical breast exam relies almost entirely on tactile judgment. There is no objective feedback to confirm adequate coverage, consistent pressure, or subtle tissue differences. Findings are often documented as “normal” or “no palpable mass,” offering little granularity, no baseline comparison, and no way to track gradual changes. This limits the exam’s sensitivity and reduces its value in clinical decision-making.
Uncertainty
When breast exam findings are uncertain, clinicians are forced to make decisions with limited objective support. This uncertainty contributes to variability in care, increased patient anxiety, and challenges in documentation, justification, and medico-legal defensibility. Even when outcomes are benign, the absence of objective data makes it harder to confidently stand behind clinical decisions.
The Solution
The Myra Scanner is your breast palpation companion that uses electrical impedance to detect the presence of tissue anomalies during a clinical breast exam.
1. Attach the conductive disposable silicone cap.
2. Hold the device in the palm of your hand.
3. Measure healthy tissue baseline.
4. Perform spot measurements as part of the palpation exam by pressing the electrodes onto the skin.
5. The device will signal the presence of tissue anomalies with a beep.
The Method
About Us
We are an early stage startup in the development phase. Reach out with questions or get involved using the form below.
Hassaan Khan, President and CEO
Hassaan brings over 10 years of medical device development experience both as an engineer and a technical lead. He has a strong passion for removing barriers between cutting medical devices and patients that need them the most.
Olivia Kuckhahn, Chief Scientific Officer
Olivia is a Ph.D. candidate at the University of Minnesota Medical School with a focus on the role of the innate immune system, specifically macrophages, in the aggressive triple-negative subtype of breast cancer. She is excited to contribute her expertise in breast cancer research to the Myra project, with the goal of directly impacting patient outcomes through the development of accessible screening technologies.
Daniel Akah, Research Specialist
Daniel has 3+ years experience of investigating biological complexities through the usage of novel biotechnologies, as well as the administrative coordination and execution of clinical trials. The catalyst behind his passion for the Myra Scanner and the translation of data-driven research into accessible health care is due to the impact that he has seen physicians make in my parents' lives, who immigrated from Africa to the United States for medical treatment and educational opportunity.
Leave us a message and we'll get back to you.
